Violeta Serra

Violeta Serra

Auto-generated profile, based on publicly available information

Violeta Serra

Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Cancer Cell
Verified
Journal Article
Closed access
SCSarat Chandarlapaty
Sarat Chandarlapaty
ASAyana Sawai
Ayana Sawai
MSMaurizio Scaltriti
Maurizio Scaltriti
VRVanessa Rodrik-Outmezguine
Vanessa Rodrik-Outmezguine
OGOlivera Grbovic-Huezo
Olivera Grbovic-Huezo
NRNeal Rosen
Neal Rosen

14 April 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
MHMaria Teresa Herrera-Abreu
Maria Teresa Herrera-Abreu
MPMarta Palafox
Marta Palafox
UAUzma Asghar
Uzma Asghar
MRMartín A. Rivas
Martín A. Rivas
RCRosalind J. Cutts
Rosalind J. Cutts
VSVioleta Serra
Violeta Serra
Small-molecule inhibitors of the CDK4/6 cell-cycle kinases have shown clinical efficacy in estrogen receptor (ER)-positive metastatic breast cancer, although their cytostatic effects are limited by primary and acquired resistance. Here we report that ER-positive breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2–mediated S-phase entry. This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, which reduced the levels of cyclin D1 (CCND1) and other G1–S cyclins, abolished pRb phosphorylation, and inhibited activation of S-phase transcriptional programs. Combined targeting of both CDK4/6 and PI3K triggered cancer cell apoptosis in vitro and in patient-derived tumor xenograft (PDX) models, resulting in tumor regression and improved disease control. Furthermore, a triple combination of endocrine therapy, CDK4/6, and PI3K inhibition was more effective than paired combinations, provoking rapid tumor regressions in a PDX model. Mechanistic investigations showed that acquired resistance to CDK4/6 inhibition resulted from bypass of cyclin D1–CDK4/6 dependency through selection of CCNE1 amplification or RB1 loss. Notably, although PI3K inhibitors could prevent resistance to CDK4/6 inhibitors, they failed to resensitize cells once resistance had been acquired. However, we found that cells acquiring resistance to CDK4/6 inhibitors due to CCNE1 amplification could be resensitized by targeting CDK2. Overall, our results illustrate convergent mechanisms of early adaptation and acquired resistance to CDK4/6 inhibitors that enable alternate means of S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents. Cancer Res; 76(8); 2301–13. ©2016 AACR.

12 February 2013 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JRJordi Rodon
Jordi Rodon
RDRodrigo Dienstmann
Rodrigo Dienstmann
VSVioleta Serra
Violeta Serra
Josep TaberneroJosep Tabernero
Josep Tabernero

30 September 2008 in Cancer Research
Verified
Journal Article
Closed access
PDF file
VSVioleta Serra
Violeta Serra
BMBen Markman
Ben Markman
MSMaurizio Scaltriti
Maurizio Scaltriti
PEPieter Eichhorn
Pieter Eichhorn
VVVanesa Valero
Vanesa Valero
JBJosé Baselga
José Baselga
Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is a common event in human cancer, either through inactivation of the tumor suppressor phosphatase and tensin homologue deleted from chromosome 10 or activating mutations of p110-α. These hotspot mutations result in oncogenic activity of the enzyme and contribute to therapeutic resistance to the anti-HER2 antibody trastuzumab. The PI3K pathway is, therefore, an attractive target for cancer therapy. We have studied NVP-BEZ235, a dual inhibitor of the PI3K and the downstream mammalian target of rapamycin (mTOR). NVP-BEZ235 inhibited the activation of the downstream effectors Akt, S6 ribosomal protein, and 4EBP1 in breast cancer cells. The antiproliferative activity of NVP-BEZ235 was superior to the allosteric selective mTOR complex inhibitor everolimus in a panel of 21 cancer cell lines of different origin and mutation status. The described Akt activation due to mTOR inhibition was prevented by higher doses of NVP-BEZ235. NVP-BEZ235 reversed the hyperactivation of the PI3K/mTOR pathway caused by the oncogenic mutations of p110-α, E545K, and H1047R, and inhibited the proliferation of HER2-amplified BT474 cells exogenously expressing these mutations that render them resistant to trastuzumab. In trastuzumab-resistant BT474 H1047R breast cancer xenografts, NVP-BEZ235 inhibited PI3K signaling and had potent antitumor activity. In treated animals, there was complete inhibition of PI3K signaling in the skin at pharmacologically active doses, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies. In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-α. [Cancer Res 2008;68(19):8022–30]

20 June 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JMJ. Mateo
J. Mateo
CLC.J. Lord
C.J. Lord
VSV. Serra
V. Serra
ATA. Tutt
A. Tutt
JBJudith Balmana
Judith Balmana
JBJ.S. de Bono
J.S. de Bono
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce tumour-specific vulnerabilities that can be exploited therapeutically. In 2009, a first-in-man clinical trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/BRCA2 deficiency. In this review, we summarize a decade of PARP inhibitor clinical development, a work that has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). Over the past 10 years, our knowledge on the mechanism of action of PARP inhibitor as well as how tumours become resistant has been extended, and we summarise this work here. We also discuss opportunities for expanding the precision medicine approach with PARP inhibitors, identifying a wider population who could benefit from this drug class. This includes developing and validating better predictive biomarkers for patient stratification, mainly based on homologous recombination defects beyond BRCA1/BRCA2 mutations, identifying DNA repair deficient tumours in other cancer types such as prostate or pancreatic cancer, or by designing combination therapies with PARP inhibitors.

20 January 2017 in Nature Reviews Cancer
Verified
Journal Article
Open access
PDF file
ABAnnette T Byrne
Annette T Byrne
DADenis G. Alférez
Denis G. Alférez
FAFrédéric Amant
Frédéric Amant
DADaniela Annibali
Daniela Annibali
Joaquín ArribasJoaquín Arribas
Joaquín Arribas
LTLivio Trusolino
Livio Trusolino
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.